[
  {
    "variant_id": {
      "Gene": "PARK2",
      "Protein_Change": {
        "ref": "Q",
        "alt": "R",
        "position": "514"
      },
      "variant_string_id": "PARK2 Q514R"
    },
    "functional_evidence_aim": "Pathogenic",
    "assessment_steps": [
      {
        "step_name": "Step 1: Define the disease mechanism",
        "extracted_paper_info": "The study aims to investigate somatic mutations of the PARK2 gene in glioblastoma and other human malignancies, with a focus on understanding the functional consequences of these mutations.",
        "judgment": "YES",
        "notes": "The paper clearly defines the disease mechanism as investigating the effects of somatic mutations on the PARK2 gene's function in glioblastoma and other human malignancies."
      },
      {
        "step_name": "Step 2: Evaluate applicability of general classes of assay used in the field",
        "extracted_paper_info": "",
        "judgment": "YES",
        "notes": "The study uses a cellular phenotype rescue assay, which is generally accepted as effective for modeling disease pathogenesis related to gene function."
      },
      {
        "step_name": "Step 3: Evaluate validity of specific instances of assays",
        "sub_steps": [
          {
            "sub_step_name": "Sub-step 3a: Basic Controls and Replicates",
            "internal_questions": [
              {
                "question": "Were basic controls included for this assay? Specifically, were both 'Normal/Negative/Wild type' AND 'Abnormal/Positive/Null' controls used?",
                "answer": "YES"
              },
              {
                "question": "Did the paper explicitly state that multiple replicates were used for the experiments?",
                "answer": "YES"
              }
            ],
            "notes": "The paper includes both wild-type and mutant controls, and states that the experiments were performed in triplicate."
          },
          {
            "sub_step_name": "Sub-step 3b: Accepted/Validated Assay (if basic controls/replicates were insufficient in 3a)",
            "internal_questions": [],
            "notes": "The specific instance of the assay has not been previously validated, but it is a widely accepted cellular phenotype rescue assay."
          },
          {
            "sub_step_name": "Sub-step 3c: Variant Controls (if basic controls/replicates were sufficient in 3a)",
            "internal_questions": [
              {
                "question": "Were variant controls used in the assay for this variant? Specifically, were known pathogenic variants used as controls?",
                "answer": "YES"
              }
            ],
            "notes": "The study uses both wild-type and mutant PARK2 proteins, including a known pathogenic variant."
          },
          {
            "sub_step_name": "Sub-step 4a: Statistical Analyses",
            "internal_questions": [],
            "notes": "The paper does not provide statistical analyses or OddsPath calculations for this specific variant."
          },
          {
            "sub_step_name": "Sub-step 4b: No OddsPath Calculation (if statistical analyses were insufficient)",
            "internal_questions": [
              {
                "question": "How many total benign/pathogenic variant controls were used across the entire study (as applicable to this variant's assay)?",
                "answer": "10 or less"
              }
            ],
            "notes": "The study uses both wild-type and mutant PARK2 proteins, including a known pathogenic variant. This totals 2 control variants."
          }
        ],
        "notes": "The specific instance of the assay is not previously validated, but it is a widely accepted cellular phenotype rescue assay. The study uses both wild-type and mutant PARK2 proteins, including a known pathogenic variant, which totals 2 control variants."
      },
      {
        "step_name": "Step 4: Apply evidence to individual variant interpretation",
        "sub_steps": [
          {
            "sub_step_name": "Sub-step 4a: Statistical Analyses",
            "internal_questions": [],
            "notes": "The paper does not provide statistical analyses or OddsPath calculations for this specific variant."
          },
          {
            "sub_step_name": "Sub-step 4b: No OddsPath Calculation (if statistical analyses were insufficient)",
            "internal_questions": [],
            "notes": "The study uses both wild-type and mutant PARK2 proteins, including a known pathogenic variant. This totals 2 control variants. With 10 or less total control variants, the functional evidence strength is Max PS3_supporting / Max BS3_supporting."
          }
        ],
        "notes": "The specific instance of the assay is not previously validated, but it is a widely accepted cellular phenotype rescue assay. The study uses both wild-type and mutant PARK2 proteins, including a known pathogenic variant, which totals 2 control variants. With 10 or less total control variants, the functional evidence strength is Max PS3_supporting / Max BS3_supporting."
      }
    ],
    "overall_conclusion": "The study investigates somatic mutations of the PARK2 gene in glioblastoma and other human malignancies using a cellular phenotype rescue assay. The specific instance of the assay is not previously validated, but it is widely accepted for modeling disease pathogenesis related to gene function. The study uses both wild-type and mutant PARK2 proteins, including a known pathogenic variant, which totals 2 control variants. With 10 or less total control variants, the functional evidence strength is Max PS3_supporting / Max BS3_supporting."
  }
]